New Investigational Drug for Systemic and Cutaneous Lupus Advancing to Phase I Clinical Trials Ventus Therapeutics Inc. has announced the development of VENT-03, a potential first-in-class drug ...

Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and ...

-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...

Phase 3 PHOENYCS GO study met the primary endpoint demonstrating clinical improvement in moderate-to-severe systemic lupus erythematosus; Clinical improvements were observed among key secondary ...

HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and ...